Petros Pharmaceuticals, Inc. [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19
	10-K	10-K	10-K	10-K
Revenues:
Prescription Medications	2.7	4.6
Medical Devices	3.3	3.2
Prescription Medication Sales			6.4
Medical Device Sales			3.2
Total revenues [+]	6.0	7.8	9.6	15.6
Products	6.0	7.8	9.6	15.6
Net interest income		0.0	0.0
Revenue growth [+]	-23.3%	-18.3%	-38.6%
Prescription Medications	-40.6%
Medical Devices	1.6%
International	-3.7%	23.4%
Cost of goods sold	2.3	1.6	4.0	7.4
Gross profit	3.7	6.2	5.5	8.2
Gross margin	61.8%	79.5%	57.7%	52.3%
Selling, general and administrative	12.2	15.6	15.7	19.7
Research and development	1.7	1.8	0.5
Other operating expenses	-3.4
EBITDA [+]	-6.9	-11.2	-10.6	-11.6
EBITDA growth	-38.6%	5.2%	-8.3%
EBITDA margin	-114.4%	-143.0%	-111.1%	-74.3%
Depreciation	0.0	0.0	6.7	5.3
EBITA	-6.9	-11.2	-17.3	-16.9
EBITA margin	-114.6%	-143.1%	-180.8%	-108.3%
Amortization of intangibles	5.6	6.9
EBIT [+]	-12.5	-18.0	-17.3	-16.9
EBIT growth	-31.0%	4.4%	2.5%
EBIT margin	-207.9%	-231.1%	-180.8%	-108.3%
Non-recurring items [+]	7.5			2.4
Asset impairment	7.5			2.4
Interest expense, net [+]	0.6
Interest expense	0.6	0.4	3.1
Interest income	0.0
Other income (expense), net [+]	0.5	9.4	-1.7	-13.8
Gain (loss) on derivative instruments	0.5	9.4	-1.7
Pre-tax income	-20.0	-9.0	-22.0	-33.2
Income taxes	0.0	0.0	-1.4	-0.6
Tax rate	0.0%	0.0%	6.5%	1.9%
Net income	-20.0	-9.0	-20.6	-32.5
Net margin	-334.4%	-115.0%	-215.3%	-208.7%

Basic EPS [+]	($9.68)	($8.25)	($3.85)	($13.22)
Growth	17.3%	114.1%	-70.8%
Diluted EPS [+]	($9.68)	($8.25)	($3.85)	($13.22)
Growth	17.3%	114.1%	-70.8%

Shares outstanding (basic) [+]	2.1	1.1	5.3	2.5
Growth	90.1%	-79.6%	117.1%
Shares outstanding (diluted) [+]	2.1	1.1	5.3	2.5
Growth	90.1%	-79.6%	117.1%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.